Fig. 8: Prognostic analysis of predictive biomarkers in combination therapy with TAS-102 plus bevacizumab. | npj Systems Biology and Applications

Fig. 8: Prognostic analysis of predictive biomarkers in combination therapy with TAS-102 plus bevacizumab.

From: Quantitative cancer-immunity cycle modeling for predicting disease progression in advanced metastatic colorectal cancer

Fig. 8

Overall survival analysis in patients with advanced mCRC based on four predictive biomarkers: the tumor-infiltrating CD8+ CTL/Treg ratio (a), the density of tumor-infiltrating CD4+ Th1 cells (b), the tumor-infiltrating CD4+ Th1/Treg ratio (c), and the density of tumor-infiltrating CD8+ CTL cells (d).

Back to article page